Fuhrman Alan — SEC Form 4 filings
SEC reporting owner CIK 1303521. 14 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-03-19 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 9,500 shares, $151,954 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: purchase of 9,500 shares @ $16.00 ($151,954) in Tyra Biosciences, Inc., filed 2024-11-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | Chief Financial Officer | 10 | 1 leg · 9,500 sh · $151,954 | — | 10 |
| SpringWorks Therapeutics, Inc. (SWTX) | Director | 3 | — | — | 9 |
| Esperion Therapeutics, Inc. (ESPR) | Director | 1 | — | — | 2 |
Form 4 filings — Fuhrman Alan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 951 @ $9.13 | EDGAR |
| 2026-05-07 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 20,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 1,376 @ $9.13 | EDGAR |
| 2025-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 701 @ $9.13 | EDGAR |
| 2025-08-07 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Disposition to issuer (D): 24,727 · Disposition to issuer (D): 29,983 (derivative) · Disposition to issuer (D): 7,464 (derivative) · Disposition to issuer (D): 15,318 (derivative) · Disposition to issuer (D): 13,774 (derivative) · Disposition to issuer (D): 12,216 (derivative) | EDGAR |
| 2025-05-15 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 10,060 @ $0 | EDGAR |
| 2025-03-18 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 1,238 @ $9.78 | EDGAR |
| 2024-11-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Purchase (P): 9,500 @ $16.00 | EDGAR |
| 2024-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 954 @ $12.48 | EDGAR |
| 2024-08-16 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 4,095 @ $0 · Grant/award (A): 12,216 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 932 @ $12.48 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1303521 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →